Single cell morphology distinguishes genotype and drug effect in Hereditary Spastic Paraplegia
Abstract A central need for neurodegenerative diseases is to find curative drugs for the many clinical subtypes, the causative gene for most cases being unknown. This requires the classification of disease cases at the genetic and cellular level, an understanding of disease aetiology in the subtypes...
Main Authors: | Gautam Wali, Shlomo Berkovsky, Daniel R. Whiten, Alan Mackay-Sim, Carolyn M. Sue |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-95995-4 |
Similar Items
-
Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery
by: Alan Mackay-Sim
Published: (2021-03-01) -
Low dose tubulin-binding drugs rescue peroxisome trafficking deficit in patient-derived stem cells in Hereditary Spastic Paraplegia
by: Yongjun Fan, et al.
Published: (2014-05-01) -
Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells
by: Gautam Wali, et al.
Published: (2020-08-01) -
A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations
by: Greger Abrahamsen, et al.
Published: (2013-03-01) -
A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations
by: Greger Abrahamsen, et al.
Published: (2015-10-01)